About EDP Biotech
EDP Biotech Corporation (EDP) is a medical device company focused on the development and sale of immunodiagnostic tests for both humans and animals. EDP utilizes over 30 years of research and development in identification and purification of proteins present in the early stages of biological changes for production of in vitro diagnostic tests whose primary target is Early Detection Products.
EDP is currently focusing on two protein biomarkers that will potentially have a significant impact upon healthcare.
The first is a tumor marker assay which detects early stage colorectal cancer using a blood sample. The biomarker has been evaluated in eighteen clinical investigations, using more than 6,000 subjects and 8,500 samples, and these tests have shown assays for the biomarker to be highly accurate in the detection of colorectal carcinoma, particularly early stage carcinoma: detecting nearly 96% of Stage 1 and 94% of Stage 2 cancers.
EDP is also developing a unique lateral flow assay that can identify those females who have not conceived. This test is based upon a protein biomarker caller ECF and is found in humans as well as a number of animals. The assay is called the EDP/ECF™ Test which can be run on samples collected as early as 24 hours after natural or artificial insemination.
